BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guven DC, Aksun MS, Cakir IY, Kilickap S, Kertmen N. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme. Future Oncol 2021;17:4405-13. [PMID: 34409854 DOI: 10.2217/fon-2021-0681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Hao Z, Li R, Wu W, Huang N, Zhang K, Hao S, Feng J, Chu J, Ji N. Association of body mass index with clinical outcome of WHO grade 4 glioma.. [DOI: 10.21203/rs.3.rs-2555288/v1] [Reference Citation Analysis]
2 Sütcüoğlu O, Erdal ZS, Akdoğan O, Çeltikçi E, Özdemir N, Özet A, Uçar M, Yazıcı O. The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective. Turk J Med Sci 2023;53:413-9. [PMID: 36945944 DOI: 10.55730/1300-0144.5599] [Reference Citation Analysis]
3 Wang W, Liu W, Xu J, Jin H. MiR-33a targets FOSL1 and EN2 as a clinical prognostic marker for sarcopenia by glioma. Front Genet 2022;13:953580. [DOI: 10.3389/fgene.2022.953580] [Reference Citation Analysis]
4 Weller J, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Schlegel U, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Pietsch T, Tzaridis T, Zeyen T, Borger V, Güresir E, Vatter H, Herrlinger U, Schneider M. Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. J Neurooncol 2022. [PMID: 35704157 DOI: 10.1007/s11060-022-04046-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Morshed RA, Young JS, Casey M, Wang EJ, Aghi MK, Berger MS, Hervey-Jumper SL. Sarcopenia Diagnosed Using Masseter Muscle Diameter as a Survival Correlate in Elderly Patients with Glioblastoma. World Neurosurg 2022;161:e448-63. [PMID: 35181534 DOI: 10.1016/j.wneu.2022.02.038] [Reference Citation Analysis]